Abstract
Background
Patients diagnosed with stage III breast cancer often undergo surgery, radiation therapy, and chemotherapy as part of their treatment. The choice of anesthesia technique during surgery has been a subject of interest due to its potential association with immune changes and prognosis. In this study, we aimed to compare the mortality rates between stage III breast cancer patients undergoing surgery with propofol-based intravenous general anesthesia and those receiving inhaled anesthetics.
Methods
Using data from Taiwan’s National Health Insurance Research Database and Taiwan Cancer Registry, we identified a cohort of 10,896 stage III breast cancer patients. Among them, 1,506 received propofol-based intravenous anesthetic maintenance, while 9,390 received inhaled anesthetic maintenance. To ensure comparability between the two groups, we performed propensity-score matching.
Results
Our findings revealed a significantly lower mortality rate in patients who received inhaled anesthetics compared to those who received propofol-based intravenous anesthesia. Sensitivity analysis further confirmed the robustness of our results.
Conclusions
This study suggests that inhaled anesthesia technique is associated with a lower mortality rate in clinical stage III breast cancer. Further research is needed to validate and expand upon these results.
Funder
China Medical University Hospital
Publisher
Public Library of Science (PLoS)
Reference38 articles.
1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;H Sung;CA: a cancer journal for clinicians,2021
2. Current and future burden of breast cancer: Global statistics for 2020 and 2040;M Arnold;The Breast,2022
3. Minimal residual disease in breast cancer: an overview of circulating and disseminated tumour cells;A Tachtsidis;Clinical & experimental metastasis,2016
4. Effects of sevoflurane on breast cancer cell function in vitro;P Ecimovic;Anticancer research,2013
5. Effects of surgery and anesthetic choice on immunosuppression and cancer recurrence;R Kim;Journal of translational medicine,2018